Scarica l'app Stockscreener
0.6923
41.82%
-0.4977
Dopo l'orario di chiusura:
.74
0.0477
+6.89%
Precedente Chiudi:
$1.19
Aprire:
$1.08
Volume 24 ore:
6.21M
Relative Volume:
4.95
Capitalizzazione di mercato:
$33.47M
Reddito:
-
Utile/perdita netta:
$-123.46M
Rapporto P/E:
-0.2663
EPS:
-2.5993
Flusso di cassa netto:
$-104.11M
1 W Prestazione:
-52.26%
1M Prestazione:
-53.22%
6M Prestazione:
-51.07%
1 anno Prestazione:
-65.73%
Intervallo 1D:
$0.67
$1.08
Intervallo di 1 settimana:
$0.67
$1.4675
Portata 52W:
$0.67
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Confronta BCAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6923 | 33.47M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-06-28 | Iniziato | ROTH Capital | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | BTIG Research | Buy |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | JP Morgan | Overweight |
| 2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
BioAtla Announces Registered Direct Offering to Advance Clinical Programs to Key Inflection PointsSan Diego, Calif., December 20, 2024 – BioAtla, Inc. (NASDAQ: BCAB), a global clinical-stage biotechnology company, disclosed on December 19, 2024, that - Defense World
BioAtla Secures $9.2M for Clinical Program Advancements - TipRanks
Bioatla stock hits 52-week low at $1.02 amid market challenges - Investing.com
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - The Manila Times
BioAtla Highlights Advancements in CAB Cancer Therapy - TipRanks
BioAtla announces $9.2 million stock and warrant sale - Investing.com
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
BioAtla Secures $9.2M Funding Through Strategic Stock Offering to Advance Clinical Programs - StockTitan
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31 - Yahoo Finance
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - The Manila Times
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year - Investing.com
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - Quantisnow
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year By Investing.com - Investing.com Canada
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - MSN
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades - MSN
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - MarketBeat
HC Wainwright Weighs in on BioAtla FY2024 Earnings - Defense World
FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright - MarketBeat
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in BioAtla Inc - GuruFocus.com
BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright - Defense World
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades (HPP:NYSE) - Seeking Alpha
HC Wainwright & Co. Downgrades BioAtla (BCAB) - MSN
BioAtla (NASDAQ:BCAB) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Head to Head Review: Alector (NASDAQ:ALEC) vs. BioAtla (NASDAQ:BCAB) - Defense World
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
BioAtla Reports Q3 2024 Financial Results and Clinical Advances - TipRanks
BioAtla reports Q3 EPS (22c), consensus (36c) - TipRanks
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
BioAtla (BCAB) Scheduled to Post Earnings on Thursday - MarketBeat
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025 - Insider Monkey
You might want to take a look at BioAtla Inc (BCAB) now - SETE News
BioAtla Inc (BCAB) stock: A year of ups and downs - US Post News
Market Insights: BioAtla Inc (BCAB)’s Notable Gain of 7.25, Closing at 2.07 - The Dwinnex
Michael Burry – Top 10 Holdings – Latest 13F - The Acquirer's Multiple
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - SETE News
Bank of Montreal Can Buys 143,521 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months - Benzinga
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
Analyzing the Impact of Earnings Reports on BioAtla Inc Inc. (BCAB) Price Performance - The InvestChronicle
BioAtla to Score Up to $133M - San Diego Business Journal
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):